Beam Therapeutics Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Investors track quarterly earnings to understand if the company is making progress toward profitability.
Investors track quarterly earnings to understand if the company is making progress toward profitability.
Board elections show shareholders approved leadership; CEO Evans leads company strategy and decisions.
Investors track quarterly earnings to understand if the company is making progress toward profitability.
Investors track quarterly earnings to understand if the company is making progress toward profitability.
License terminations and new agreements affect what diseases Beam can treat and where it can sell products.
Annual reports show total yearly revenue, spending, and cash remaining to fund future drug development.
Stocky reads Beam Therapeutics Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Beam Therapeutics Inc.'s most recent tracked filing was a 10-Q on 4 Aug 2026: Reported Q2 2026 financial results on August 4.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.